One of the most important — and sometimes overlooked — benefits of GLP-1 medications is their effect on insulin resistance. Whether you are taking Wegovy or Ozempic (semaglutide) or Mounjaro (tirzepatide), these medications do far more than reduce appetite. They work at a cellular level to improve the way your body responds to insulin, with benefits that go well beyond the number on the scale.

This article explains what insulin resistance is, how GLP-1 medications help, and what you can do alongside treatment to get the most out of it.

What is insulin resistance?

Insulin is a hormone produced by the pancreas. After you eat, blood glucose (sugar) rises, and insulin acts as a key that allows glucose to enter cells — particularly muscle cells, fat cells and liver cells — where it is used for energy or stored.

In insulin resistance, cells do not respond properly to insulin. The key still fits the lock, but the lock turns more slowly. To compensate, the pancreas produces more insulin. Over time, the pancreas may struggle to keep up, blood glucose begins to rise, and the person develops prediabetes or type 2 diabetes.

Insulin resistance is closely linked to:

It is estimated that around 40% of adults in high-income countries have some degree of insulin resistance, many without knowing it.

How do GLP-1 medications improve insulin resistance?

GLP-1 (glucagon-like peptide-1) is a natural gut hormone released after eating. It stimulates insulin secretion, suppresses glucagon (a hormone that raises blood sugar), slows gastric emptying and signals fullness to the brain. GLP-1 medications mimic or enhance this hormone. They improve insulin resistance through several mechanisms:

1. Weight loss reduces visceral fat

Visceral fat — the fat stored around internal organs — is metabolically active. It releases inflammatory signals that directly impair insulin signalling in liver and muscle cells. Clinical trials of semaglutide (STEP 1, SUSTAIN-6) and tirzepatide (SURMOUNT-1) show significant reductions in visceral fat, which closely correlate with improvements in insulin sensitivity markers such as HOMA-IR (a standard measure of insulin resistance).

2. Direct effects on liver and muscle cells

GLP-1 receptors are present not only in the pancreas but also in the liver and skeletal muscle. Research published in Cell Metabolism (2023) and the Journal of Clinical Endocrinology & Metabolism (2024) shows that GLP-1 receptor agonists directly reduce liver fat (hepatic steatosis), decrease hepatic glucose output and improve glucose uptake in muscle cells — all of which reduce insulin resistance independently of weight loss.

3. Reduction of chronic inflammation

Chronic low-grade inflammation is both a cause and a consequence of insulin resistance. GLP-1 medications have demonstrated anti-inflammatory properties — reducing circulating markers such as CRP, IL-6 and TNF-alpha. This anti-inflammatory effect helps break the vicious cycle between inflammation and insulin resistance.

4. Tirzepatide's additional GIP effect

Mounjaro (tirzepatide) acts on both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP independently improves insulin sensitivity in adipose tissue and may enhance the uptake of glucose in fat cells after meals. This dual action may partly explain why tirzepatide shows somewhat greater improvements in blood glucose control and insulin resistance markers compared with semaglutide alone in head-to-head studies such as SURPASS-2.

What does the clinical evidence say?

The evidence is robust. Key findings from major trials:

Importantly, improvements in insulin resistance begin within the first weeks of treatment — even before significant weight loss has occurred — suggesting the direct cellular effects of GLP-1 receptor activation contribute meaningfully alongside the weight-loss component.

Who benefits most?

While everyone taking GLP-1 medication will experience some improvement in insulin sensitivity, certain groups see the greatest impact:

What can you do alongside medication to amplify the effect?

GLP-1 medication provides a powerful foundation, but lifestyle choices can significantly amplify the improvement in insulin resistance:

Exercise — especially resistance training

Skeletal muscle is the largest consumer of glucose in the body. Building and maintaining muscle through resistance training (weight lifting, bodyweight exercises) directly improves insulin sensitivity in muscle cells. Even a single session of moderate exercise improves glucose uptake for up to 48 hours. Aim for at least 150 minutes of moderate aerobic activity plus 2–3 resistance training sessions per week.

Diet quality

You don't need a perfect diet, but certain choices matter. Prioritise:

Adequate sleep

Even a single night of poor sleep (less than 6 hours) can increase insulin resistance the following day. Chronic sleep deprivation is a significant and underappreciated driver of insulin resistance. Prioritising 7–9 hours of sleep per night complements the metabolic benefits of GLP-1 treatment.

Stress management

Chronic stress elevates cortisol, which raises blood glucose and worsens insulin resistance. Mindfulness, regular physical activity and social connection all help manage the stress response.

How to track your improvement

Ask your doctor to include the following in your routine blood tests if you have insulin resistance:

Most people on GLP-1 medication see measurable improvements in these markers within 3–6 months of treatment at a therapeutic dose.

Medical disclaimer

This article is for informational purposes only and does not constitute medical advice. Always consult your doctor or healthcare provider about your individual situation, treatment options and monitoring plan. Do not adjust or stop your medication without medical guidance.

Sources